The global biologics arm of AstraZeneca.

AgonOx, MedImmune partner to progress OX40 agonist applications for cancer treatment Today announced that it has entered into an exclusive global partnership with MedImmune AgonOx, the global biologics arm of AstraZeneca, to build up agonists using its OX40 system. MedImmune will lead additional preclinical and clinical research of this tumor-specific T-cell immunity stimulator for the potential treatment of cancers. We are very pleased to collaborate with MedImmune to progress our OX40 agonist applications, said AgonOx CEO Llew Keltner, M.D., Ph.D. MedImmune has amazing capabilities in immuno-oncology, and we believe offers great prospect of eventually bringing therapies using the OX40 mechanism to trigger tumorspecific immune responses to patients.Further information about Critical Treatment Pharmacology, future courses within the series and the AACN-Elsevier/MC Strategies partnership can be acquired through the National Teaching Institute and Essential Care Exposition, May 15-20, in Washington, D.C.

3Sbio, Isotechnika Pharma sign commercialization and advancement agreement for voclosporin inhibitor Isotechnika Pharma Inc. , a biopharmaceutical company centered on the discovery and advancement of immune modulating therapeutics, and 3SBio Inc. , a leading China-based biotechnology company centered on researching, developing, marketing and manufacturing biopharmaceutical items, announced the signing of a development and commercialization contract for voclosporin today, a next era calcineurin inhibitor being created for use in the prevention of organ rejection pursuing transplantation and the treating autoimmune diseases.